BIOSTAR PHARMACEUTICALS, INC. (NASDAQ:BSPM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders
Meeting of Shareholders at its executive offices in Xianyang
City, Shaanxi Province, Peoples Republic of China at 9 am (local
time) on June 9, 2017. Set forth below are the matters voted upon
at the meeting and the voting results. On the record date of
April 13, 2017, there were 2,662,652 shares of the Companys
common stock issued and outstanding and entitled to vote for each
of the proposals submitted to a vote of the Companys stockholders
at the Annual Meeting, of which 1,606,526, or 60.34%, were
present in person or represented by proxy, which constituted a
quorum.
Ronghua Wang, King-fai Leung, Haipeng Wu, Zhanxiang Ma and
Qinghua Liu as directors of the Company to hold office until the
next Annual Meeting of shareholders and until their successors
are duly elected. A summary of votes cast follows below:
|
Name
|
Voted for
|
Votes Withheld
|
Broker Non-Votes
|
|||||||||
|
Ronghua Wang
|
522,427
|
7,045
|
1,077,054
|
|||||||||
|
King-fai Leung
|
522,140
|
7,332
|
1,077,054
|
|||||||||
|
Haipeng Wu
|
507,014
|
22,458
|
1,077,054
|
|||||||||
|
Zhanxiang Ma
|
507,141
|
22,331
|
1,077,054
|
|||||||||
|
Qinghua Liu
|
507,451
|
22,021
|
1,077,054
|
voted to ratify the appointment of Mazars CPA Limited as the
Companys independent registered public accounting firm for the
year ending December 31, 2017 by the following vote:
|
Votes for
|
Votes against
|
Abstain
|
Broker Non-Votes
|
|||||||||||
|
1,571,191
|
18,844
|
16,941
|
n/a
|
shareholders voted to approve the 2017 Stock Compensation Plan by
the following vote:
|
Votes for
|
Votes against
|
Abstain
|
Broker Non-Votes
|
|||||||||||
|
495,623
|
28,984
|
4,863
|
1,077,056
|
About BIOSTAR PHARMACEUTICALS, INC. (NASDAQ:BSPM)
Biostar Pharmaceuticals, Inc. (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China). The Company offers over-the-counter (OTC) products and prescription-based pharmaceuticals. The Company’s products are sold in approximately 30 provinces in the PRC through a network of over 60 distributors and through approximately 230 sales people. The Company’s products include XinAoxing Oleanolic Acid Capsule, Ganwang Compound Paracetamol Capsule, Tianqi Dysmenorrhea Capsule, Compound Paracetamol and Amantadine Hydrochloride Tablets, Deafness Tongqiao pills and Huangyangning Tablets.
